Overview Dividends

(EXEL) Exelixis - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US30161Q1040

Cabozantinib, Cobimetinib, Minnebropan, Zanzalintinib, XL309

EPS (Earnings per Share)

EPS Growth (3y CAGR): 231.38%
EPS Trend (3y Corr): 90.0%

Last SUE: 0.52σ
Qual. Beats: 0

Revenue

Revenue Growth (3y CAGR): 13.31%
Revenue Trend (3y Corr): 81.8%

Last SUE: 0.04σ
Qual. Beats: 0

Risk via 10d forecast
Volatility	36.1%
Value at Risk 5%th	47.3%
Relative Tail Risk	-20.41%

Reward TTM
Sharpe Ratio	0.58
Alpha	12.31

Character TTM
Hurst Exponent	0.330
Beta	0.564
Beta Downside	0.279

Drawdowns 3y
Max DD	25.34%
Mean DD	6.42%
Median DD	5.75%

Description: EXEL Exelixis October 30, 2025

Exelixis, Inc. (NASDAQ:EXEL) is a U.S.-based oncology biotech that develops, markets, and sells targeted therapies for hard-to-treat cancers. Its flagship products are CABOMETYX (cabozantinib tablets) for advanced renal cell carcinoma post-anti-angiogenic therapy and COMETRIQ (cabozantinib capsules) for progressive metastatic medullary thyroid cancer; both inhibit multiple tyrosine kinases (MET, AXL, RET, VEGF). The company also commercializes COTELLIC (MEK inhibitor) in combination for advanced melanoma and MINNEBRO (mineralocorticoid-receptor antagonist) for hypertension in Japan.

Pipeline highlights include zanzalintinib (next-gen TKI targeting VEGF, MET, TAM kinases), XL309 (USP1 inhibitor for BRCA-mutated tumors), XB010 (5T4-directed ADC with MMAE payload), and XL495 (PKMYT1 inhibitor). Exelixis maintains a broad collaboration network with partners such as Ipsen, Takeda, Roche, Genentech, BMS, and Merck, leveraging co-development and licensing to diversify risk and accelerate access.

Recent performance metrics (FY 2023) show total revenue of roughly $1.2 billion, driven primarily by cabozantinib sales exceeding $1 billion, and a 12 % year-over-year increase in operating cash flow, reflecting strong market uptake in RCC and medullary thyroid cancer. The oncology biotech sector is benefitting from a projected 8 % CAGR through 2028, driven by aging populations, expanding indications for targeted agents, and sustained FDA approval pipelines.

For a deeper quantitative assessment of EXELs valuation, the ValueRay platform offers a concise, data-driven dashboard worth reviewing.

EXEL Stock Overview

Market Cap in USD	11,344m
Sub-Industry	Biotechnology
IPO / Inception	2000-04-07
Return 12m vs S&P 500	7.78%
Analyst Rating	3.90 of 5

EXEL Dividends

Currently no dividends paid

EXEL Growth Ratios

Metric	Value
CAGR 3y	36.10%
CAGR/Max DD Calmar Ratio	1.42
CAGR/Mean DD Pain Ratio	5.62
Current Volume	2195.4k
Average Volume	2440.4k

Piotroski VR‑10 (Strict, 0-10) 7.0

Net Income (677.9m TTM) > 0 and > 6% of Revenue (6% = 137.3m TTM)

FCFTA 0.27 (>2.0%) and ΔFCFTA 12.38pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 44.95% (prev 55.50%; Δ -10.56pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.28 (>3.0%) and CFO 791.0m > Net Income 677.9m (YES >=105%, WARN >=100%)

Net Debt (-199.8m) to EBITDA (862.9m) ratio: -0.23 <= 3.0 (WARN <= 3.5)

Current Ratio 3.75 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (278.5m) change vs 12m ago -4.44% (target <= -2.0% for YES)

Gross Margin 96.63% (prev 96.25%; Δ 0.37pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 79.12% (prev 70.32%; Δ 8.81pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -20.75 (EBITDA TTM 862.9m / Interest Expense TTM -40.1m) >= 6 (WARN >= 3)

Altman Z'' 4.04

(A) 0.36 = (Total Current Assets 1.40b - Total Current Liabilities 373.8m) / Total Assets 2.82b

(B) -0.04 = Retained Earnings (Balance) -106.1m / Total Assets 2.82b

(D) -0.15 = Book Value of Equity -102.2m / Total Liabilities 662.8m

Total Rating: 4.04 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 93.71

1. Piotroski 7.0pt = 2.0

2. FCF Yield 7.15% = 3.58

3. FCF Margin 32.91% = 7.50

4. Debt/Equity 0.08 = 2.50

5. Debt/Ebitda -0.23 = 2.50

6. ROIC - WACC (= 21.68)% = 12.50

7. RoE 31.64% = 2.50

8. Rev. Trend 81.79% = 6.13

9. EPS Trend 90.02% = 4.50

What is the price of EXEL shares?

As of November 20, 2025, the stock is trading at USD 42.14 with a total of 2,195,362 shares traded.
Over the past week, the price has changed by -3.33%, over one month by +22.00%, over three months by +12.31% and over the past year by +22.46%.

Is EXEL a buy, sell or hold?

Exelixis has received a consensus analysts rating of 3.90. Therefore, it is recommended to buy EXEL.

Strong Buy: 7
Buy: 4
Hold: 9
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the EXEL price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	45	6.8%
Analysts Target Price	45	6.8%
ValueRay Target Price	51	21.1%

EXEL Fundamental Data Overview November 20, 2025

Market Cap USD = 11.34b (11.34b USD * 1.0 USD.USD)
P/E Trailing = 17.7059
P/E Forward = 14.7493
P/S = 4.9577
P/B = 5.2923
P/EG = 2.2685
Beta = 0.413
Revenue TTM = 2.29b USD
EBIT TTM = 833.1m USD
EBITDA TTM = 862.9m USD
Long Term Debt = 176.5m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 25.0m USD (from shortTermDebt, last fiscal year)
Debt = 176.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -199.8m USD (from netDebt column, last quarter)
Enterprise Value = 10.53b USD (11.34b + Debt 176.5m - CCE 988.5m)
Interest Coverage Ratio = -20.75 (Ebit TTM 833.1m / Interest Expense TTM -40.1m)
FCF Yield = 7.15% (FCF TTM 753.1m / Enterprise Value 10.53b)
FCF Margin = 32.91% (FCF TTM 753.1m / Revenue TTM 2.29b)
Net Margin = 29.63% (Net Income TTM 677.9m / Revenue TTM 2.29b)
Gross Margin = 96.63% ((Revenue TTM 2.29b - Cost of Revenue TTM 77.2m) / Revenue TTM)
Gross Margin QoQ = 96.89% (prev 96.57%)
Tobins Q-Ratio = 3.73 (Enterprise Value 10.53b / Total Assets 2.82b)
Interest Expense / Debt = 14.91% (Interest Expense 26.3m / Debt 176.5m)
Taxrate = 23.31% (58.8m / 252.4m)
NOPAT = 638.9m (EBIT 833.1m * (1 - 23.31%))
Current Ratio = 3.75 (Total Current Assets 1.40b / Total Current Liabilities 373.8m)
Debt / Equity = 0.08 (Debt 176.5m / totalStockholderEquity, last quarter 2.16b)
Debt / EBITDA = -0.23 (Net Debt -199.8m / EBITDA 862.9m)
Debt / FCF = -0.27 (Net Debt -199.8m / FCF TTM 753.1m)
Total Stockholder Equity = 2.14b (last 4 quarters mean from totalStockholderEquity)
RoA = 24.01% (Net Income 677.9m / Total Assets 2.82b)
RoE = 31.64% (Net Income TTM 677.9m / Total Stockholder Equity 2.14b)
RoCE = 35.93% (EBIT 833.1m / Capital Employed (Equity 2.14b + L.T.Debt 176.5m))
RoIC = 29.82% (NOPAT 638.9m / Invested Capital 2.14b)
WACC = 8.14% (E(11.34b)/V(11.52b) * Re(8.09%) + D(176.5m)/V(11.52b) * Rd(14.91%) * (1-Tc(0.23)))
Discount Rate = 8.09% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -5.67%
[DCF Debug] Terminal Value 80.97% ; FCFE base≈621.1m ; Y1≈748.3m ; Y5≈1.21b
Fair Price DCF = 76.37 (DCF Value 20.48b / Shares Outstanding 268.1m; 5y FCF grow 21.86% → 3.0% )
EPS Correlation: 90.02 | EPS CAGR: 231.4% | SUE: 0.52 | # QB: 0
Revenue Correlation: 81.79 | Revenue CAGR: 13.31% | SUE: 0.04 | # QB: 0

Additional Sources for EXEL Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle